Publications by authors named "C S Somogyi"
Embryonic limb bud-derived micromass cultures are valuable tools for investigating cartilage development, tissue engineering, and therapeutic strategies for cartilage-related disorders. This collection of fine-tuned protocols used in our laboratories outlines step-by-step procedures for the isolation, expansion, and differentiation of primary mouse limb bud cells into chondrogenic micromass cultures. Key aspects covered in these protocols include synchronized fertilization of mice (Basic Protocol 1), tissue dissection, cell isolation, micromass formation, and culture optimization parameters, such as cell density and medium composition (Basic Protocol 2).
View Article and Find Full Text PDFArticle Synopsis
- Much of the skeletal system develops through endochondral ossification, particularly in early fetal life, making it difficult to study initial chondrogenesis in living organisms.
- Researchers are highly interested in improving methods for culturing chondrogenic cells to effectively regenerate articular cartilage and restore joint function.
- The article outlines various protocols, including a micromass culture system for chick embryo-derived cells, high-efficiency cell transfection, and histochemical detection techniques for assessing cartilage matrix production.
Background: ATX-101 (deoxycholic acid injection) is the only injectable drug approved for submental fat (SMF) reduction. In the phase 3 REFINE trials, adults with moderate or severe SMF who were dissatisfied with the appearance of their face/chin were eligible to receive up to 6 treatment sessions with ATX-101 (2 mg/cm2) or placebo. Primary and secondary endpoints, evaluated at 12 weeks after last treatment, significantly favored ATX-101 supporting its efficacy for reducing SMF and the psychological impact of SMF, and increasing satisfaction with the appearance of the face/chin.
View Article and Find Full Text PDFBackground: Various onabotulinumtoxinA doses are effective in treating forehead lines (FHL), with a trend toward lower doses.
Objective: To evaluate efficacy and safety of onabotulinumtoxinA dose-ranging treatment of FHL when the frontalis area and glabellar complex are treated together.
Materials And Methods: Adults with moderate-to-severe FHL received onabotulinumtoxinA 40 U (FHL, 20 U; glabellar lines [GL], 20 U), 30 U (FHL, 10 U; GL, 20 U), or placebo.